SUVEN LIFE SCIENCES LTD - quarterly results - for Q3 FY 13-14(DEC,2013) - REVENUE UP 92%; PAT UP 370% YoY - EXCELLENT PERFORMANCE

SUVEN LIFE SCIENCES LTD

Financial Highlights

for the 3rd Quarter ended Dec’ 2013

·       Growth in revenue Rs 1203 Mn vs.Rs 628 Mn - Up by 92%

·       Growth in PAT Rs 364 Mn vs. Rs 78 Mn - Up by 370%

·       Growth in EBIDTA Rs 557 Mn vs. Rs 152 Mn - Up by 266%

·       EPS Stands at Rs.3.12 against Rs.0.66 in Q3 FY 13 (Rs.3.9 in previous Qtr).

·       The annualized EPS comes to Rs.3.12 x 4 = 12.48. Current market price is Rs.77. The PE Ratio comes to 6.17. The pace at which Suven is progressing with its sales, Profits and  new Products, it deserves much better valuations in the market.

Financial Highlights

for 9 months period ended Dec’ 2013

·       Growth in revenue Rs 3836 Mn vs.Rs 1837 Mn - Up by 109%

·       Growth in PAT Rs 1118 Mn vs. Rs 222 Mn - Up by 403%

·       Growth in EBIDTA Rs 1734 Mn vs. Rs 401 Mn - Up by 333%

·       9 months EPS stands at Rs.9.57 against Rs.1.90 in 9 months of previous year.

·       The growth in profit was a result of prelaunch supplies of 3 products under CRAMS.

·       Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 356 Mn (9.27% on revenue) for the Nine months period ended Dec ’ 2013 for the accounting year 2013-14.

·       SUVN-502 undergoing phase 1b clinical trial in USA.

*  *  *  E  N  D  *  *  *

SUVEN LIFE SCIENCES Ltd - RESULTS FOR Q4 FY 2013 and fy 2013 - PAT UP good improvement

SUVEN LIFE SCIENCES LIMITED

RESULTS FOR Q4 FY 2013

Suven‘s PAT up by 115% for the year ended Mar 2013

14 May’ 2013 :  – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, has announced its audited financial results for the quarter and year ended 31st Mar 2013. 

Financial Highlights

 for the 4th Quarter ended Mar’ 2013:

Ø Growth in revenue Rs 747 Mn vs.Rs 629 Mn - Up by 23%

Ø Growth in PAT Rs 86 Mn vs. Rs 71 Mn - Up by 21%

Ø Growth in EBIDTA Rs 141 Mn vs. Rs 135 Mn - Up by 4%

Financial Highlights

for the year ended Mar’ 2013:

Ø Growth in revenue Rs 2579 Mn vs.Rs 2042 Mn - Up by 26%

Ø Growth in PAT Rs 308 Mn vs. Rs 144 Mn - Up by 115%

Ø Growth in EBIDTA Rs 542 Mn vs. Rs 250 Mn - Up by 117%

Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 347 Mn (13.4% on revenue) for the year ended Mar’ 2013.

The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the year 2012-13.

OTHER NEWS ON SUVEN DURING LAST 2 YEARS :

May 10, 2013 :-Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia.

April 17, 2013 : -Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New Zealand

Feb 12, 2013 : -Suven‘s PAT up by 500 % for the quater ended Dec 2012

Dec 31, 2012 :-Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada.

Dec 13, 2012 :-Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea

Nov 15, 2012:-Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012

Oct 04, 2012 :-Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”

Aug 14, 2012 :-Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012

Aug 09, 2012 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New Zealand.

July 13, 2012 :-Suven to Present at Alzheimer's Association International Conference (AAIC)

May 22, 2012 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and Eurasia

May 04, 2012 :-Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012

April 03, 2012 :--Suven Life Sciences secures 4 Product Patents for their NCEs in China and Korea

February 07, 2012 :-Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA

January 31, 2012 :-Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011

December 08, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and Canada

November 14, 2011:-Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-2011) Annual Meeting at Washington DC, USA

November 1, 2011:-Suven‘s revenue up by 31% and spends 18% of revenue on R&D;

October4, 2011:-Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”

September 22, 2011:-Suven Participating at 4th CNS Partnering & Deal Making Conference in USA

September 5, 2011 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New Zealand

August 18, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the world

August 13, 2011:-Suven‘s revenue up by 24% and spends 17% of revenue on R&D

July 18, 2011:-Suven presenting at International Conference on Alzheimer’s disease (ICAD)

June 20, 2011:-Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world

May 30, 2011:-Suven Spends 20.5% of Revenue on R&D’   PAT up by 48.55% for the year ending March 2011

May 26, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the world

May 18, 2011:-Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS)

May 09, 2011:-Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”

April 26, 2011:-Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world

April 5, 2011:-SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCE

Jan 31, 2011:-Suven spends 24% of revenue on R&D;   PAT up by 55% for for the 3rd quarter ending Dec 2010;

Jan 11, 2011:-Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011

*  *  *  E  N  D  *  *  *

SUVEN LIFE SCIENCES LTD - FIRST QUARTER RESULTS - Q1 FY2013 - NET SALES UP 58%;NPT UP 137% YoY

SUVEN LIFE SCIENCES LTD

FIRST QUARTER RESULTS

Q1 FY2013

SUVEN LIFE SCIENCES is a  smaller Pharma Firm, which is progressing  gradually each quarter.

Here are its results for the first quarter ending  June 2012.

HIGH LIGHTS

Net Sales for Q1 FY 13 stands at Rs.70.53 Cr; up by 12.82% from the previous quarter of Q4 FY 12 (Rs.62.51 Cr); and up by  58.02 % from the corresponding Quarter of Q1 FY 12 (Rs.44.63 Cr).

Total Expenditure for Q1 FY 13 stands at Rs.59.02 Cr; up by 16.04% from the previous quarter of Q4 FY 12 (Rs.50.86 Cr); and up by  44.49% from the corresponding Quarter of Q1 FY 12 (Rs.   40.85 Cr).

Profit before Interest, Dep. & Taxes for Q1 FY 13 stands at Rs.11.50 Cr; down  by -1.25% from the previous quarter of Q4 FY 12 (Rs.11.65 Cr); and up by  204.06% from the corresponding Quarter of Q1 FY 12 (Rs.    3.38 Cr).

Net Profit for Q1 FY 13 stands at Rs.7.96 Cr; down  by -4.12% from the previous quarter of Q4 FY 12 (Rs.8.31 Cr); and up by  136.94% from the corresponding Quarter of Q1 FY 12 (Rs.  3.36 Cr).

Diluted EPS for Q1 FY 13 stands at Rs.0.68 ; Rs.0.71 in Q4 FY 12; Rs.0.29 in Q1 FY12 on a Face Value of Rs.1.

52 week high/low price : 18.90/11.10; Current Market price is also around Rs.18.30.

Paid-up Equity  is low at 11.67 Cr; Of this Public Holding is around 36.56%.

Suven claims to achieve a number of discoveries and patents periodically. Its Sales and profits are improving gradually from quarter to quarter. This will be an interesting company to watch.

RESULTS TABLE

Suven Life Sciences	30-Jun-12	QoQ % Dif	31-Mar-12	YoY%dif	30-Jun-11	31-Dec-11	30-Sep-11
Net Sales	7052.72	12.82	6251.37	58.02	4463.29	4863.7	4804.38
Total Expenditure	5902.25	16.04	5086.33	44.49	4084.92	4944.58	4705.95
Profit before Interest, Dep. & Taxes	1150.47	-1.25	1165.04	204.06	378.37	-80.88	98.43
Net Profit	796.34	-4.12	830.55	136.94	336.09	129.45	256.12
Diluted EPS	0.68	-4.23	0.71	134.48	0.29	0.11	0.22
Net Sales	7052.72	12.82	6251.37	58.02	4463.29	4863.7	4804.38
Cost of materials consumed	2144.63	-12.99	2464.72	15.67	1854.11	2125.68	1678.55
Employee benefits	651.73	29.43	503.54	38.23	471.47	583.66	594.21
Depreciation	183.23	33.46	137.29	32.08	138.73	138.27	140.02
Other expenses	2591.82	68.86	1534.92	58.89	1631.23	2976.45	2385.9
Total expenses	5902.25	16.04	5086.33	44.49	4084.92	4944.58	4705.95
Profit before tax	881.02	-2.35	902.25	274.79	235.07	-138.12	67.74
Tax Expenses	84.68	18.1	71.7	-183.82	-101.02	-267.57	-188.38
Net Profit	796.34	-4.12	830.55	136.94	336.09	129.45	256.12
Face Value(Rs )	1	0	1	0	1	1	1
Paid-up Equity	1167.32	0	1167.32	0	1167.32	1167.32	1167.32
Diluted EPS	0.68	-4.23	0.71	134.48	0.29	0.11	0.22
Public holding (%)	36.56	0	36.56	-0.44	36.72	36.56	36.86

 *  *  *  E  N  D  *  *